Topical roflumilast foam 0.3% NDA submitted to the FDA for the treatment of seborrheic dermatitis in adults and adolescents
Arcutis Biotherapeutics, Inc., an early commercial-stage company focused on developing meaningful innovations in immuno-dermatology, announced the submission of a New Drug Application (NDA) to the FDA for roflumilast foam 0.3% for the treatment of moderate to severe seborrheic dermatitis in adults and adolescents. Roflumilast foam 0.3% is an investigational once-daily topical foam formulation of a highly potent and selective phosphodiesterase type 4 (PDE4) inhibitor being developed to treat inflammatory dermatoses, particularly in hair-bearing areas of the body such as the scalp, face, and trunk